About this trial
5 to 10% of cancers are due to the presence of a constitutional genetic alteration. It can be inherited from parents (family form) or by accident, in the first moments of life after fertilization (sporadic form). In both cases, this genetic alteration is constitutional and transmissible to descendants. It is hereditary. When an hereditary early form is suspected, several well-known genes generally involved in genetic predispositions to cancer are found by a technique called " gene panel ". However, this analysis does not always identify the genetic predisposing factors for cancer. New techniques called "high-throughput exome sequencing (SHD-E)", allow more than the analysis of the the gene panel. These analysis allow to identify alterations in other genes that could contribute to the development of cancer. The objective of the Ex²trican study is to show, from patients with early cancer (sporadic or familial form), that this approach to exome sequencing can be effective to identify new genetic risk of cancer, when the first panel analysis of genes is negative.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Major or minor patient
Histological or cytological evidence of malignant tumor diagnosis
Patient with cancer before age 40 (or before age 30 for breast cancer).
Absence of anomaly found on the oncogenetic panel tested in the predisposition concerned
Disqualifiers
Refusal of the patient participation
Psychiatric illness and / or condition of the patient compromising the understanding of the information or the realization of the study
Patient under guardianship, curatorship or safeguard of justice
Pregnant woman
Trial design
Single group
Treatments tested in this trial
blood sample
Geneticblood test
Treatment groups
Trial outcomes
Primary outcomes
genetic mutations
SHD-E analysis
Sponsors and contacts
Click on the lead sponsor to view all of their trials.